Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05661227
Other study ID # Liuxin2022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date June 30, 2024

Study information

Verified date December 2022
Source Hebei Medical University Third Hospital
Contact Xin Liu
Phone 18810525281
Email 1536149525@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As a simple auxiliary tool for lower extremity orthopedic surgery, tourniquet can effectively reduce intraoperative bleeding and ensure the clarity of the operative field, effectively shorten the operation time and improve the operation efficiency. The extensive use of tourniquets in lower extremity surgery will not only cause local paralysis, pain and other complications, but also bring about postoperative complications such as large drainage volume and deep vein thrombosis. Recent studies have found that tourniquet induced ischemia-reperfusion injury not only affects the local tissue structure and function of skeletal muscle, but also causes reperfusion injury in distant organs (such as heart, lung and brain). Therefore, improving tourniquet ischemia-reperfusion injury after knee replacement is of great significance to improve the quality of life of patients during the perioperative period. Therefore, the aim of this study was to investigate the effects of dexmedetomidine and tourniquet pretreatment on myocardial injury and brain injury caused by lower extremity ischemia-reperfusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date June 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - Patients undergoing TKA under general anesthesia - Voluntarily sign the informed consent - ASA Grade I to III - BMI 18-28 kg/m2 Exclusion Criteria: - Congenital heart disease or history of cardiac surgery, heart conduction disease, frequent ventricular/atrial premature beats, atrial fibrillation and other serious arrhythmias - Severe liver disease and kidney disease - Temporary and permanent pacemaker implantation - Patients with serious central nervous system diseases or serious mental disorders - Recent history of sedation, antidepressant or opioid use - Body mass index >35kg/m2 - Participants in other clinical trials within 1 month prior to study enrollment.

Study Design


Intervention

Drug:
Dexmedetomidine
Whether apply DEX or not
0.9% Sodium chloride
Whether apply DEX or not
Device:
Tourniquet(Early)
Timing of tourniquet application
Tourniquet(Late)
Timing of tourniquet application

Locations

Country Name City State
China The Third Hospital of Hebei Medical University Shijiazhuang City Hebei
China The Third Hospital of Hebei Medical University Shijiazhuang City Hebei

Sponsors (1)

Lead Sponsor Collaborator
Hebei Medical University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary SOD Superoxide dismutase Baseline to day2
Primary MDA Malonaldehyde Baseline to day2
Primary IL-6 Interleukin- 6 Baseline to day2
Primary TNF-a Tumor necrosis factor-a Baseline to day2
Primary hs-Tn High sensitive troponin Baseline to day2
Primary BDNF Brain-derived neurotrophic factor Baseline to day2
Secondary HRV HeartRateVariability Baseline to day2
Secondary PRR Pulse Repetition Rate Baseline to day2
Secondary BP Blood Pressure(both systolic and diastolic blood pressure will be measured) Baseline to day2
Secondary SpO2 Peripheral capillary oxygen saturation Baseline to day2
Secondary VAS Visual Analogue Scale/Score(Draw a 10cm horizontal line on the paper. One end of the horizontal line is 0, indicating no pain; the other end is 10, indicating severe pain; the middle part indicates pain. Different degrees of pain. Let the patient draw a mark on the horizontal line according to his own feelings to indicate the degree of pain.) Baseline to day2
Secondary MMSE Mini-mental State Examination(The scale includes the following seven aspects: time orientation, place orientation, instant recall, attention and computational power, delayed memory, language, and whether to answer correctly or not. The test scores are closely related to the educational level. The normal threshold is more than 20 points, and the junior high school and above are more than 24 points) Baseline to day2
See also
  Status Clinical Trial Phase
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Recruiting NCT01476969 - Effect of Remote Ischemic Perconditioning on Acute Kidney Injury in Adult Valve Replace N/A
Completed NCT03050489 - Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Recruiting NCT02940600 - Efficacy Evaluation of Normothermic Perfusion Machine Preservation in Liver Transplant Using Very Old Donors N/A
Recruiting NCT02729155 - Single-cycle Remote Ischemic Preconditioning and Postconditioning for Prevention of Contrast-Induced Nephropathy N/A
Recruiting NCT02649309 - Single-cycle Remote Ischemic Preconditioning and Postconditioning (SCRIP) Trial N/A
Completed NCT02290080 - Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers Phase 3
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Terminated NCT01726465 - Methylprednisolone N Acetylcysteine in Hepatic Resections Phase 2
Completed NCT03535623 - RIPC During Free Flap With Preoperative Radiotherapy N/A
Completed NCT02581618 - Remote Ischemic Preconditioning in Elective Percutaneous Interventions N/A
Recruiting NCT04000334 - Early Transcranial Doppler Goal Directed Therapy After Cardiac Arrest: a Pilot Study N/A
Completed NCT01887171 - Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus N/A
Recruiting NCT05148715 - Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY) Phase 2
Completed NCT04257240 - Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
Active, not recruiting NCT05708053 - Cardio-protective Effect of Metformin in Patients Undergoing PCI Phase 3
Completed NCT05194306 - PERTRIAL - Perla® Preservation Solution N/A
Recruiting NCT05179434 - A Study of Retrograde Reperfusion of Renal Graft to Reduce Ischemic-reperfusion Injury N/A
Not yet recruiting NCT04951791 - Lipid Emulsion in Cardiac Valve Replacement Surgery N/A
Completed NCT01666587 - Ischemia Reperfusion: Prostaglandins and Antioxidants N/A